engleski

Comparative Randomized Pilot Study of Azithromycin and Doxycycline Efficacy and Tolerability in the Treatment of Prostate Infection Caused by Ureaplasma urealyticum

A total of 1442 patients with symptoms of chronic prostatitis were examined over a 4 year period at the Outpatient Department for Urogenital Infections, University Hospital for Infectious Diseases "Dr. Fran Mihaljević", Zagreb, Croatia. Ureaplasma urealyticum was the causative pathogen in 72 patients with chronic prostatitis. The following data were obtained for each patient: clinical history, clinical status includng digitorectal examination, urethral swab specimens, selective samples of urine and EPS, according to the 4-glass localization test (Meares and Stamey localization technique). Ureaplasma urealyticum was confirmed by semiquantitative culturing and the antimicrobial susceptibility test Mycoplasma duo 62740 Sanofi, Diagnostics Pasteur. The inclusion criteria for chronic prostatitis caused by Ureaplasma urealyticum was the presence of clinical symptoms, presence of U. urealyticum in EPS or VB3, absence of U. urealyticum in urethral swabs and absence of other possible pathogens of chronic prostatitis in EPS or VB3. The patients were randomized according to a computer randomization list to receive a total dose of 4, 5 g of azithromycin given as a 3-day therapy of 1 x 500 mg weekly for 3 weeks or doxycyline 100 mg b.i.d. for 21 days. Patients` sexual partners were treated at the same time. Clinical efficacy and tolerability of administered drug were evaluated during, at the end and 4-6 weeks after completion of therapy. Bacteriological efficacy was evaluated 4-6 weeks after completion of therapy. A total of 63 patients with prostate infection caused by U. urealyticum were available for this pilot study. Treatment groups did not differ regarding age, distribution of urethral, prostatic, sexual and other symptoms, and according to digitorectal prostatic examination. Five patients treated with doxycycline had nausea. In the group of patients with prostate infection caused by U. urealyticum, the eradication rate was not significantly different with regards to the administered azithromycin (25/32) or doxycycline (23/31). Clinical cure did not significantly differ with regards to the administered azithromycin (22/32) or doxycycline (21/31).

Azithromycin; doxycycline; prostate infection; Chlamydia trachomatis

nije evidentirano